Orthopaedics

Addressing a significant unmet need in biological meniscus augmentation and anterior cruciate ligament (ACL) reconstruction.

Orthopaedics

Addressing a significant unmet need in biological meniscus augmentation and anterior cruciate ligament (ACL) reconstruction.

A regenerative approach to soft tissue repair and return to pre-injury activity

An acute soft tissue joint injury can significantly affect the quality of life of a previously healthy and active individual.

The team at TRX Orthopaedics are changing the way health care professionals can treat these injuries.  

Our patented dCELL® Technology products provide a natural alternative to harvesting and transplanting the patient’s own ligaments or tendons, eliminating any donor site complications (a second surgical site), supporting  a replicable surgery, saving operating room time and simplifying rehabilitation.

Its natural acellular matrix structure allows the patient to repopulate the graft with their own native cells.

Our dCELL® Technology is being used to develop new regenerative approaches to repairing damaged knees. 

With an aging population,  increasing number of sports related injuries and rising levels of obesity, the global orthopaedic market is currently valued at an estimated $46bn with the sports medicine sector valued at $4.5bn.

Tissue Regenix is addressing these problems through their portfolio of  biological regenerative solutions.

Applying the dCELL Technology to various tissues; OrthoPure™ XM (porcine meniscus) and OrthoPure™ XT (porcine tendon) as well as OrthoPure™ HM (donated human meniscus) and OrthoPure™ HT (donated human tendon)  produces a scaffold to replace the damaged tissue that will  re-populate with the patient’s own cells. 

dCELL Technology also offers the surgical team a strong and consistently sized scaffold which makes surgical planning simpler and the surgery faster and more reproducible. The scaffold requires no special storage conditions, it is transported and stored at room temperature which helps improve operating room efficiencies and logistics.  

The company has conducted clinical trials for both OrthoPure XM and XT within the EU and upon CE mark approval expects the first OrthoPure XT tendons to be available in Mid-2017. 

OrthoPure products are currently not available in the US under FDA regulations.